Equities analysts predict that Arbutus Biopharma Corp (NASDAQ:ABUS) will announce earnings per share (EPS) of ($0.35) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Arbutus Biopharma’s earnings, with estimates ranging from ($0.36) to ($0.34). Arbutus Biopharma reported earnings of ($0.44) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 20.5%. The firm is scheduled to issue its next quarterly earnings report on Thursday, August 1st.
On average, analysts expect that Arbutus Biopharma will report full year earnings of ($1.32) per share for the current financial year, with EPS estimates ranging from ($1.78) to ($0.65). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.09) per share, with EPS estimates ranging from ($1.57) to ($0.53). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Arbutus Biopharma.
Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.16). The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.18 million. Arbutus Biopharma had a negative return on equity of 95.26% and a negative net margin of 1,237.92%.
A number of analysts recently weighed in on the stock. Zacks Investment Research cut shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a report on Friday, January 18th. BidaskClub raised shares of Arbutus Biopharma from a “hold” rating to a “buy” rating in a research note on Tuesday, March 5th. ValuEngine lowered shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Chardan Capital reaffirmed a “buy” rating and issued a $6.50 price objective on shares of Arbutus Biopharma in a research note on Sunday, March 10th. Finally, Echelon Wealth Partners reaffirmed a “hold” rating on shares of Arbutus Biopharma in a research note on Monday, March 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $6.25.
A number of institutional investors have recently bought and sold shares of ABUS. BNP Paribas Arbitrage SA bought a new position in Arbutus Biopharma in the 1st quarter worth $26,000. Jefferies Group LLC bought a new position in shares of Arbutus Biopharma during the 1st quarter worth about $36,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Arbutus Biopharma during the 1st quarter worth about $78,000. Legal & General Group Plc increased its holdings in shares of Arbutus Biopharma by 367.7% during the 3rd quarter. Legal & General Group Plc now owns 24,540 shares of the biopharmaceutical company’s stock worth $232,000 after purchasing an additional 19,293 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Arbutus Biopharma by 140.4% during the 1st quarter. The Manufacturers Life Insurance Company now owns 26,188 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 15,296 shares in the last quarter. 43.96% of the stock is owned by hedge funds and other institutional investors.
Shares of ABUS stock traded down $0.06 on Friday, reaching $2.40. 127,791 shares of the stock were exchanged, compared to its average volume of 259,025. The company has a market cap of $135.30 million, a price-to-earnings ratio of -2.35 and a beta of 1.61. The company has a quick ratio of 12.75, a current ratio of 12.75 and a debt-to-equity ratio of 0.06. Arbutus Biopharma has a 1-year low of $2.18 and a 1-year high of $12.60.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.
Featured Story: Terms to Better Understand Call Options
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.